科研之友
微信
新浪微博
Facebook
分享链接
摘要
Objective: The purpose of this study was to examine the safety and clinical efficacy of computed tomography (CT)-guided radioactive iodine-125 (I-125) seed implantation treatment in patients with spinal metastatic tumors. Methods: We retrospectively analyzed 20 cases of spinal metastatic tumors, including nine men and eleven women aged 50-79 years (mean age: 61.1 years). We used treatment planning system (TPS) to construct three-dimensional images of the spinal metastatic tumors and to determine what number and dose rate distribution to use for the I-125 seeds. The matched peripheral dose of the I-125 seed implantation was 90-130 Gy. Twenty-four spinal metastatic tumors were treated by CT-guided radioactive I-125 seed implantation. A median of 19 (range: 4-43) I-125 seeds were implanted. Results: Twenty cases were followed for a median of 15.3 months (range: 7-32 months). The rate of pain relief was 95%. The median control time for all of the patients was 12.5 months. The 3-, 6-, and 12-month cumulative local control rates were 100%, 95%, and 60%, respectively. The median survival time for all of the patients was 16 months. The cumulative 6- and 12-month survival rates were 100% and 78.81%, respectively. No major complications were observed. No I-125 seeds were lost or migrated to other tissues or organs. Conclusion: CT-guided radioactive I-125 seed implantation is a safe, effective, and minimally invasive method for the treatment of patients with spinal metastatic tumors. It is a possible alternative therapy for the treatment of spinal metastases.
